310 related articles for article (PubMed ID: 33031861)
1. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
Lipsitz O; Di Vincenzo JD; Rodrigues NB; Cha DS; Lee Y; Greenberg D; Teopiz KM; Ho RC; Cao B; Lin K; Subramaniapillai M; Flint AJ; Kratiuk K; McIntyre RS; Rosenblat JD
Am J Geriatr Psychiatry; 2021 Sep; 29(9):899-913. PubMed ID: 33478865
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract][Full Text] [Related]
5. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Gill H; Nasri F; Ling R; Teopiz KM; Ho RC; Subramaniapillai M; Kratiuk K; Mansur RB; Jones BDM; Lee Y; Rosenblat JD
J Affect Disord; 2021 Nov; 294():592-596. PubMed ID: 34332360
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
[TBL] [Abstract][Full Text] [Related]
7. Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.
Di Vincenzo JD; Lipsitz O; Rodrigues NB; Jones BDM; Gill H; Lee Y; Lui LMW; Teopiz KM; Ho R; Lin K; Nasri F; McIntyre RS; Rosenblat JD
Psychiatry Res; 2022 Jan; 307():114321. PubMed ID: 34890909
[TBL] [Abstract][Full Text] [Related]
8. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
Danayan K; Chisamore N; Rodrigues NB; Vincenzo JDD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; Teopiz KM; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 May; 323():115133. PubMed ID: 36889160
[TBL] [Abstract][Full Text] [Related]
9. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
[TBL] [Abstract][Full Text] [Related]
10. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Gill H; Subramaniapillai M; Kratiuk K; Nasri F; Mansur RB; Rosenblat JD
CNS Spectr; 2022 Jun; 27(3):322-330. PubMed ID: 33267928
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review.
Dai D; Miller C; Valdivia V; Boyle B; Bolton P; Li S; Seiner S; Meisner R
BMC Psychiatry; 2022 Feb; 22(1):140. PubMed ID: 35193541
[TBL] [Abstract][Full Text] [Related]
12. Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Cha DS; Gill H; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
J Psychiatr Res; 2021 Apr; 136():444-451. PubMed ID: 32948309
[TBL] [Abstract][Full Text] [Related]
13. Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.
McIntyre RS; Rodrigues NB; Lipsitz O; Lee Y; Cha DS; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Ho R; Mansur RB; Rosenblat JD
J Affect Disord; 2021 Jun; 288():210-216. PubMed ID: 33965843
[TBL] [Abstract][Full Text] [Related]
14. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Subramaniapillai M; Kratiuk K; Majeed A; Nasri F; Gill H; Mansur RB; Rosenblat JD
Psychiatry Res; 2021 Jun; 300():113860. PubMed ID: 33836470
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
Chisamore N; Danayan K; Rodrigues NB; Di Vincenzo JD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; McIntyre RS; Rosenblat JD
J Psychopharmacol; 2023 Aug; 37(8):775-783. PubMed ID: 37194253
[TBL] [Abstract][Full Text] [Related]
16. Distinct trajectories of antidepressant response to intravenous ketamine.
O'Brien B; Lijffijt M; Lee J; Kim YS; Wells A; Murphy N; Ramakrishnan N; Swann AC; Mathew SJ
J Affect Disord; 2021 May; 286():320-329. PubMed ID: 33770540
[TBL] [Abstract][Full Text] [Related]
17. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
[TBL] [Abstract][Full Text] [Related]
18. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
[TBL] [Abstract][Full Text] [Related]
19. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review.
Sakurai H; Jain F; Foster S; Pedrelli P; Mischoulon D; Fava M; Cusin C
J Affect Disord; 2020 Nov; 276():660-666. PubMed ID: 32871698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
